Osteoporosis, as a musculoskeletal disease, is very common, especially in the era of aging society. It is described by a reduction in bone strength and increased risk of fractures, which are linked to considerable morbidity, mortality, and high healthcare burdens. Bisphosphonates are the most commonly used drugs to manage osteoporosis and they consequently reduce fracture risk. However, one of the clinical challenges is fear of side effects in patients who are using bisphosphonates as the administration of these drugs is lengthy. Ocular inflammation has been reporting as one of the potential vision-threatening side effects of bisphosphonates.
Purpose
To review previously reported ocular inflammation in patients taking bisphosphonates.
Method
A literature survey was conducted using databases in order to collect data for a narrative review of published reports regarding ocular side effects of bisphosphonates.
Results
People taking bisphosphonates were at a relatively low risk of ocular inflammation, with the onset from a few hours after exposure up to more than 3 years. The release of inflammatory mediators mainly by activated gamma delta T cells in response to bisphosphonates was the main cause of ocular inflammation.
Conclusion
Strategies for treating patients with osteoporosis should consider the potential ocular side effects of bisphosphonates. Ocular inflammation, as one of the side effects of bisphosphonates, is a serious sight-threatening sign and should be taken seriously. Greater awareness of the association between bisphosphonate use and ocular inflammation may allow for earlier identification and timely treatment of future cases.
NouraeinejadA. Handbook of ocular drugs, and ocular side effects of systemic drugs. Tehran: Tabib Publication, 2000.
2.
NouraeinejadA. Differential diagnosis in optometry and ophthalmology. Second Edition. Iran: Noruzi Publication, 2017.
3.
GarrigaCPazianasMHawleyS,et al.Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study. Ann N Y Acad Sci2018; 1415: 34–46.
4.
LewieckiEM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis2010; 1: 115–128.
5.
CawthonPM. Gender differences in osteoporosis and fractures. Clin Orthop Relat Res2011; 469: 1900–1905.
6.
AlswatKA. Gender disparities in osteoporosis. J Clin Med Res2017; 9: 382–387.
7.
SatoMGreaserWEndoN, et al.Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest1991; 88: 2095–2105.
8.
EtminanMAminzadehKMatthewIR,et al.Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol2008; 35: 691–695.
9.
KennelKADrakeMT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc2009; 84: 632–7.quiz 638.
10.
EtminanMForooghianFMaberleyD. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Can Med Assoc J2012; 184: E431–E434.
11.
MarakaSKennelKA. Bisphosphonates for the prevention and treatment of osteoporosis. BMJ : British Medical Journal2015; 351: h3783.
12.
Godkhindi VishwapriyaMBasade MaheboobM. Zoledronic acid induced orbital cellulitis-case report & literature review. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)2016; 15: 75–79.
13.
Martin GuillénSHurtado GarciaRAlvarez CienfuegosA. Uveitis due to bisphosphonates: a rare Side effect?Reumatol Clin2016; 12: 119.
14.
UmunakweOCHerrenDKimSJ,et al.Diffuse ocular and orbital inflammation after zoledronate infusion—case report and review of the literature. Digit J Ophthalmol2017; 23: 109–112.
15.
Gomez EscobarLGDeviaDG. Possible ocular adverse effects attributed to bisphoshonate therapy: two care reports. Rev Colomb Reumatol2017; 24: 54–59.
16.
SchilcherJMichaëlssonKAspenbergP. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med2011; 364: 1728–1737.
17.
RuggieroSLMehrotraBRosenbergTJ,et al.Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg2004; 62: 527–534.
18.
WooSGHellsteinJWKalmarJR. Narrative review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med2006; 144: 753–761.
19.
van den WyngaertTHuizingMTVermomkenJB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?Ann Oncol2006; 17: 1197–1204.
20.
HawleySLealJDelmestriA, et al.Anti-Osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. Journal of Bone and Mineral Research :the Official Journal of the American Society for Bone and Mineral Research2016; 31: 2008–2015.
21.
HeckbertSRLiGCummingsSR, et al.Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med2008; 168: 826–831.
22.
GreenJCzannerGReevesG, et al.Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. Br Med J2010; 341: c4444.
23.
FarrellKBKarpeiskyAThammDH,et al.Bisphosphonate conjugation for bone specific drug targeting. Bone Rep2018; 9: 47–60.
24.
FredianiBGiustiABianchiG, et al.Clodronate in the management of different musculoskeletal conditions. Minerva Med2018; 109: 300–325.
25.
BernardiSDi GirolamoMNecozioneS, et al.Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience. Musculoskelet Surg2019; 103: 47–53.
26.
TakeyamaSShinodaH. Pharmacological actions and pharmacokinetics of bisphosphonates. Clin Calcium2003; 13: 115–121.
27.
ClarkEMDurupD. Inflammatory eye reactions with bisphosphonates and other osteoporosis medications: what are the risks?Ther Adv Musculoskelet Dis2015; 7: 11–16.
28.
FraunfelderFWFraunfelderFT. Adverse ocular drug reactions recently identified by the national registry of drug-induced ocular Side effects. Ophthalmology2004; 111: 1275–1279.
29.
PetersonJDBedrossianEH. Bisphosphonate-associated orbital inflammation—a case report and review. Orbit2012; 31: 119–123.
30.
HewittRELissinaAGreenAE,et al.The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol2005; 139: 101–111.
31.
KassiGPapamichaelKPapaioannouG, et al.Cytokines and insulin resistance after zoledronic acid-induced acute phase response. Immunol Invest2014; 43: 544–555.
32.
MammoZGuoMMaberleyD,et al.Oral bisphosphonates and risk of wet age-related macular degeneration. Am J Ophthalmol2016; 168: 62–67.
33.
KunzmannVBauerEWilhelmM. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med1999; 340: 737–738.
34.
McClungMHarrisSTMillerPD, et al.Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med2013; 126: 13–20.
35.
SautyAPecherstorferMZimmer-RothI,et al.Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and patients with malignancy. Bone1996; 18: 133–139.
36.
ThiébaudDSautyABurckhardtP,et al.An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int1997; 61: 386–392.
37.
DicuonzoGVincenziBSantiniD, et al.Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine2003; 23: 649–654.
38.
DielIJBergnerRGrötzKA. Adverse effects of bisphosphonates: current issues. J Support Oncol2007; 5: 475–482.
39.
OrCCuiJMatsubaraJ,et al.Pro-inflammatory and anti-angiogenic effects of bisphosphonates on human cultured retinal pigment epithelial cells. Br J Ophthalmol2013; 97: 1074–1078.
RoelofsAJJauhiainenMMönkkönenH,et al.Peripheral blood monocytes are responsible for gamma-delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol2009; 144: 245–250.
42.
FraunfelderFWFraunfelderFTJensvoldB. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol2003; 135: 219–222.
43.
PatelDVHorneAHouseM,et al.The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology2013; 120: 773–776.
RichardsJCWiffenSJ. Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea2006; 25: 1100–1101.
61.
StackRTarrK. Drug-induced optic neuritis uveitis secondary to bisphosphonates. NZ Med J2006; 119: U1888.
62.
FrenchDMargoC. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina2008; 28: 889–893.
KilickapSOzdamarYAltundagMK,et al.A case report: zoledronic acid-induced anterior uveitis. Med Oncol2008; 25: 238–240.
65.
MooreMMBeithJM. Acute unilateral anterior uveitis and scleritis following a single infusion of zoledronate for metastatic breast cancer. Med J Aust2008; 188: 370–371.
66.
PhillipsPMNewmanSA. Orbital inflammatory disease after intravenous infusion of zoledronate for treatment of metastatic renal cell carcinoma. Arch Ophthalmol2008; 126: 137–139.
67.
SharmaNSOoiJLMasselosK,et al.Zoledronic acid infusion and orbital inflammatory disease. N Engl J Med2008; 359: 1410–1411.
68.
TanYLSimsJCheeSP. Bilateral uveitis secondary to bisphosphonate therapy. Ophthalmologica2009; 223: 215–216.
McKagueMJorgensonDBuxtonKA. Ocular side effects of bisphosphonates: a case report and literature review. Can Fam Physician2010 Oct; 56: 1015–1017.
72.
ProcianoyFProcianoyE. Orbital inflammatory disease secondary to a single-dose administration of zoledronic acid for treatment of postmenopausal osteoporosis. Osteoporos Int2010; 21: 1057–1058.
73.
YangEBBirkholzESLeeAG. Another case of bisphosphonateinduced orbital inflammation. J Neuroophthalmol2010; 30: 94–95.
74.
VidalMAMedinaCTorresLM. Seguridad de losbisfosfonatos. Rev Soc Esp Dolor2011; 18: 43–55.
75.
RahimyELawSK. Orbital inflammation after zoledronate infusion: an emerging complication. Can J Ophthalmol2013; 48: e11–e12.
76.
PazianasMClarkEEikenP,et al.Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database. J Bone Miner Res2013; 28: 455–463.
77.
BrulinskiPNikapotaAD. Zolendronic acid-induced retrobulbar optic neuritis: a case report. Clin Oncol (R CollRadiol)2013; 25: 328–329.
78.
PatelDVBollandMNisaZ, et al.Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int2015; 26: 499–503.
79.
PirbhaiARajakSNGooldLA, et al.Bisphosphonate-induced orbital inflammation: a case series and review. Orbit2015; 34: 331–335.
SethAAndersonDPAlbianiDA,et al.Orbital inflammation and optic neuropathy with zoledronic acid for metastatic prostate cancer. Can J Ophthalmol2009; 44: 467–468.
82.
MissottenGVerheezenY. Orbital inflammation after use of zoledronic acid for metastasized prostate carcinoma. Bull Société Belge Ophtalmol2010; (315): 23–24.
83.
YeoJJaferAK. Zolendronate associated inflammatory orbital disease. N Z Med J2010; 123: 50–52.
84.
VoraMRodgersRUretskyS. Nitrogen bisphosphonate-induced orbital inflammatory disease: gamma delta t cells—a report and review of 2 cases. Ophthal Plast Reconstr Surg2014; 30: e84–e85.
85.
Cordero-ComaMSalazar-MéndezRGarzo-GariaI,et al.Drug-induced uveitis. Expert Opin Drug Saf2015; 14: 111–126.
86.
ReidIRGambleGDMesenbrinkP,et al.Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab2010; 95: 4380–4387.
NussenblattRBLeeRWChewE, et al.Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for prevention. Am J Ophthalmol2014; 158: 5–11.
89.
SeddonJMGenslerGMiltonRC,et al.Association between C-reactive protein and age-related macular degeneration. JAMA2004; 291: 704–710.
90.
JonesDGSavageRHightonJ. Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. Br Med J2005; 330: 74.
